Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients
This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We u...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2002-08, Vol.74 (4), p.573-576, Article 573 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 576 |
|---|---|
| container_issue | 4 |
| container_start_page | 573 |
| container_title | Transplantation |
| container_volume | 74 |
| creator | FISHER, Robert A SAGGI, Bob H FERREIRA-GONZALEZ, Andrea WOLFE, Luke POSNER, Marc P |
| description | This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We used plasma samples from which nucleic acid was extracted. Quantification was determined by using an internal standard that contained the same primer sequences as for HCMV. During treatment, weekly QPCR assays were performed. Patients were treated with HCMV immunoglobulin-G for a finite period, but intravenous ganciclovir was continued until less than 100 viral copies (vc) per mL was detectable. After cessation of therapy, patients were followed for 6 months with monthly clinical assessment and QPCR. No patient developed recurrence of HCMV at a mean follow-up of 16 months. This preliminary study suggests that the use of QPCR to assess viral load is useful in deciding the length of HCMV treatment with ganciclovir but requires further randomized validation. |
| doi_str_mv | 10.1097/00007890-200208270-00025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72130048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72130048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-254cb916fccd3f398c2c77ae059802661116546c8b0e9c2103da9f55df0626eb3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EoqXwCsgb2KVc2_HfBglV5UeqBAtYRx7nejBK4tRORpqH6DvjmQ4Usak3tuzv-FydQwhlcMnA6ndQlzYWGg7AwXANTb3h8gk5Z1K0jQIDT_85n5EXpfyqiBRaPydnjAvJLefn5O5bTmVGv8Qd0p0bYu-WmCaaAr1d3bTExR2f5jTsR8yuIPU_XZxoRuePZEiZjm5yWxxxWg5Cv1_SiFs3pF3Ma6F9LHgQVlVJ1aFJeesmumQ3lXmoJnSuJlVcXpJnwQ0FX532C_Lj4_X3q8_NzddPX64-3DS-5XxpuGz9xjIVvO9FENZ47rV2CNIa4EoxxpRslTcbQOs5A9E7G6TsAyiucCMuyNv7f-ecblcsSzfG4nGow2BaS6c5EwCteRRkRnGwVlfQ3IO-5lkyhm7OcXR53zHoDp11fzrr_nbWHTur0tcnj3UzYv8gPJVUgTcnwBXvhlBz87E8cMJYa5Wo3Pv_ZvDH-tJUo47D45P8BpQhtQ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18620997</pqid></control><display><type>article</type><title>Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>FISHER, Robert A ; SAGGI, Bob H ; FERREIRA-GONZALEZ, Andrea ; WOLFE, Luke ; POSNER, Marc P</creator><creatorcontrib>FISHER, Robert A ; SAGGI, Bob H ; FERREIRA-GONZALEZ, Andrea ; WOLFE, Luke ; POSNER, Marc P</creatorcontrib><description>This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We used plasma samples from which nucleic acid was extracted. Quantification was determined by using an internal standard that contained the same primer sequences as for HCMV. During treatment, weekly QPCR assays were performed. Patients were treated with HCMV immunoglobulin-G for a finite period, but intravenous ganciclovir was continued until less than 100 viral copies (vc) per mL was detectable. After cessation of therapy, patients were followed for 6 months with monthly clinical assessment and QPCR. No patient developed recurrence of HCMV at a mean follow-up of 16 months. This preliminary study suggests that the use of QPCR to assess viral load is useful in deciding the length of HCMV treatment with ganciclovir but requires further randomized validation.</description><identifier>ISSN: 1534-6080</identifier><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-200208270-00025</identifier><identifier>PMID: 12352922</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adolescent ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cytomegalovirus Infections - diagnosis ; Cytomegalovirus Infections - drug therapy ; Ganciclovir - therapeutic use ; Humans ; Kidney Transplantation - adverse effects ; Liver Transplantation - adverse effects ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Polymerase Chain Reaction - methods ; Prospective Studies ; Viral Load</subject><ispartof>Transplantation, 2002-08, Vol.74 (4), p.573-576, Article 573</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-254cb916fccd3f398c2c77ae059802661116546c8b0e9c2103da9f55df0626eb3</citedby><cites>FETCH-LOGICAL-c422t-254cb916fccd3f398c2c77ae059802661116546c8b0e9c2103da9f55df0626eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13899963$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12352922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FISHER, Robert A</creatorcontrib><creatorcontrib>SAGGI, Bob H</creatorcontrib><creatorcontrib>FERREIRA-GONZALEZ, Andrea</creatorcontrib><creatorcontrib>WOLFE, Luke</creatorcontrib><creatorcontrib>POSNER, Marc P</creatorcontrib><title>Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We used plasma samples from which nucleic acid was extracted. Quantification was determined by using an internal standard that contained the same primer sequences as for HCMV. During treatment, weekly QPCR assays were performed. Patients were treated with HCMV immunoglobulin-G for a finite period, but intravenous ganciclovir was continued until less than 100 viral copies (vc) per mL was detectable. After cessation of therapy, patients were followed for 6 months with monthly clinical assessment and QPCR. No patient developed recurrence of HCMV at a mean follow-up of 16 months. This preliminary study suggests that the use of QPCR to assess viral load is useful in deciding the length of HCMV treatment with ganciclovir but requires further randomized validation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cytomegalovirus Infections - diagnosis</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Ganciclovir - therapeutic use</subject><subject>Humans</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Liver Transplantation - adverse effects</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Prospective Studies</subject><subject>Viral Load</subject><issn>1534-6080</issn><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EoqXwCsgb2KVc2_HfBglV5UeqBAtYRx7nejBK4tRORpqH6DvjmQ4Usak3tuzv-FydQwhlcMnA6ndQlzYWGg7AwXANTb3h8gk5Z1K0jQIDT_85n5EXpfyqiBRaPydnjAvJLefn5O5bTmVGv8Qd0p0bYu-WmCaaAr1d3bTExR2f5jTsR8yuIPU_XZxoRuePZEiZjm5yWxxxWg5Cv1_SiFs3pF3Ma6F9LHgQVlVJ1aFJeesmumQ3lXmoJnSuJlVcXpJnwQ0FX532C_Lj4_X3q8_NzddPX64-3DS-5XxpuGz9xjIVvO9FENZ47rV2CNIa4EoxxpRslTcbQOs5A9E7G6TsAyiucCMuyNv7f-ecblcsSzfG4nGow2BaS6c5EwCteRRkRnGwVlfQ3IO-5lkyhm7OcXR53zHoDp11fzrr_nbWHTur0tcnj3UzYv8gPJVUgTcnwBXvhlBz87E8cMJYa5Wo3Pv_ZvDH-tJUo47D45P8BpQhtQ0</recordid><startdate>20020827</startdate><enddate>20020827</enddate><creator>FISHER, Robert A</creator><creator>SAGGI, Bob H</creator><creator>FERREIRA-GONZALEZ, Andrea</creator><creator>WOLFE, Luke</creator><creator>POSNER, Marc P</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20020827</creationdate><title>Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients</title><author>FISHER, Robert A ; SAGGI, Bob H ; FERREIRA-GONZALEZ, Andrea ; WOLFE, Luke ; POSNER, Marc P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-254cb916fccd3f398c2c77ae059802661116546c8b0e9c2103da9f55df0626eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cytomegalovirus Infections - diagnosis</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Ganciclovir - therapeutic use</topic><topic>Humans</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Liver Transplantation - adverse effects</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Prospective Studies</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FISHER, Robert A</creatorcontrib><creatorcontrib>SAGGI, Bob H</creatorcontrib><creatorcontrib>FERREIRA-GONZALEZ, Andrea</creatorcontrib><creatorcontrib>WOLFE, Luke</creatorcontrib><creatorcontrib>POSNER, Marc P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FISHER, Robert A</au><au>SAGGI, Bob H</au><au>FERREIRA-GONZALEZ, Andrea</au><au>WOLFE, Luke</au><au>POSNER, Marc P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2002-08-27</date><risdate>2002</risdate><volume>74</volume><issue>4</issue><spage>573</spage><epage>576</epage><pages>573-576</pages><artnum>573</artnum><issn>1534-6080</issn><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We used plasma samples from which nucleic acid was extracted. Quantification was determined by using an internal standard that contained the same primer sequences as for HCMV. During treatment, weekly QPCR assays were performed. Patients were treated with HCMV immunoglobulin-G for a finite period, but intravenous ganciclovir was continued until less than 100 viral copies (vc) per mL was detectable. After cessation of therapy, patients were followed for 6 months with monthly clinical assessment and QPCR. No patient developed recurrence of HCMV at a mean follow-up of 16 months. This preliminary study suggests that the use of QPCR to assess viral load is useful in deciding the length of HCMV treatment with ganciclovir but requires further randomized validation.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>12352922</pmid><doi>10.1097/00007890-200208270-00025</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1534-6080 |
| ispartof | Transplantation, 2002-08, Vol.74 (4), p.573-576, Article 573 |
| issn | 1534-6080 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72130048 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Cytomegalovirus Infections - diagnosis Cytomegalovirus Infections - drug therapy Ganciclovir - therapeutic use Humans Kidney Transplantation - adverse effects Liver Transplantation - adverse effects Medical sciences Middle Aged Pharmacology. Drug treatments Polymerase Chain Reaction - methods Prospective Studies Viral Load |
| title | Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T06%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20validation%20of%20quantitative%20polymerase%20chain%20reaction%20for%20management%20of%20cytomegalovirus%20disease%20in%20solid-organ%20transplant%20patients&rft.jtitle=Transplantation&rft.au=FISHER,%20Robert%20A&rft.date=2002-08-27&rft.volume=74&rft.issue=4&rft.spage=573&rft.epage=576&rft.pages=573-576&rft.artnum=573&rft.issn=1534-6080&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-200208270-00025&rft_dat=%3Cproquest_cross%3E72130048%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18620997&rft_id=info:pmid/12352922&rfr_iscdi=true |